The spread of the omikron variant of the coronavirus was the main topic of discussion at the European summit. The leaders of the member states of the European Union discussed, among other things, the rules for free travel. Because is being vaccinated with two doses of a corona vaccine still enough to cross the border to another country?
Yes, it was decided. And that still nine months after the administration of the second vaccine (or the first in the case of Johnson & Johnson), said European Commission President Ursula von der Leyen. The Commission recommends booster shots at the latest six months after full vaccination, followed by a ‘grace period’ of three months. After those nine months, the corona certificate of the person concerned will therefore no longer be valid if the booster shot has not been taken.
Customized Vaccines
Furthermore, at the European summit it was decided that the member states of the European Union will order a first tranche of more than 180 million doses of modified vaccines from Pfizer-BioNTech. “Our contracts provide that the companies will develop modified vaccines upon request within 100 days,” explained European Commission President von der Leyen. “In this context, I am pleased to announce that member states have agreed to activate a first tranche of more than 180 million additional doses of modified vaccines in the third contract with Pfizer-BioNTech.”
The Commission signed a third contract with Pfizer-BioNTech in May to purchase up to 1.8 billion vaccines. This will allow Member States to purchase up to 900 million doses of the first vaccine and of vaccines adapted to variants, with an option for an additional 900 million doses.
Escape
According to von der Leyen, the highly contagious omikron variant is spreading “with relentless speed”. The variant also has the potential to at least partially escape current vaccines, she added. Yet, according to von der Leyen, Europe is better armed these days than a year ago, when the delta variant started to advance. At that time, the vaccination campaigns had yet to get off the ground. Now up to 300 million doses per month can be produced in the EU.
— .